Davis Polk advised Morgan Stanley & Co. LLC and Goldman, Sachs & Co. as joint book-running managers on Mylan N.V.’s $2 billion SEC-registered secondary offering of 35,000,000 ordinary shares sold by certain subsidiaries of Abbott Laboratories. The ordinary shares are listed on the NASDAQ Global Select Market under the symbol “MYL.”
Mylan N.V. (“Mylan”) is a global pharmaceutical company committed to setting new standards in health care. Mylan offers a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, Mylan offers a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. Mylan also operates one of the largest active pharmaceutical ingredient manufacturers and currently markets products in about 145 countries and territories.
The Davis Polk capital markets team included partner Michael Kaplan and associates Ferrell Maguire, Skawenniio Barnes and Jennifer Wang. The intellectual property team included partner Frank J. Azzopardi and associate David He. Counsel Alon Gurfinkel provided tax advice. Members of the Davis Polk team are based in the New York and London offices.
Source: www.davispolk.com
